CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application

Area of Science:

• Immunology
• Cellular Engineering
• Oncology

Background:

• Chimeric antigen receptors (CARs) are engineered receptors that direct immune cells to target specific antigens.
• CAR T cell therapy, utilizing T cells engineered with CARs, shows promise in treating hematological malignancies.
• Current CAR T cell therapy faces limitations, prompting exploration of alternative immune effector cells.

Purpose of the Study:

• To review the functional characteristics of CARs in diverse immune cell types.
• To evaluate the preclinical and clinical efficacy of CAR-engineered cells beyond T cells.
• To assess the safety profile of novel CAR-based immunotherapies.

Main Methods:

• Literature review of preclinical studies and clinical trials involving CARs in various immune cells.
• Analysis of CAR domain structures and their impact on signaling and effector functions.
• Comparative assessment of CAR cell therapy efficacy and safety across different leukocyte types.

Main Results:

• CARs can be successfully expressed in various innate and adaptive immune cells, enhancing their cytotoxic potential.
• Studies demonstrate promising efficacy of non-T cell CARs against tumors in preclinical models.
• Initial clinical data suggest potential benefits and manageable safety profiles for alternative CAR cell therapies.

Conclusions:

• Engineering diverse immune cells with CARs offers a promising strategy to overcome limitations of CAR T cell therapy.
• Further research into CAR function across different immune cell types is crucial for developing next-generation cancer immunotherapies.
• CAR cell therapy holds potential for broader applications in treating various cancers, with ongoing investigations into safety and efficacy.